Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for VitaNova Life Sciences's PB Ratio or its related term are showing as below:
VNOV'
s PB Ratio Range Over the Past 10 Years
Min: 1.9 Med: 6.22 Max: 21.76
Current: 6.22
During the past 9 years, VitaNova Life Sciences's highest PB Ratio was 21.76. The lowest was 1.90. And the median was 6.22.
VNOV's PB Ratio is not ranked
in the Medical Distribution industry.
Industry Median: 0.99
vs VNOV: 6.22
During the past 12 months, VitaNova Life Sciences's average Book Value Per Share Growth Rate was 66.90% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of VitaNova Life Sciences was 21.90% per year. The lowest was -215.80% per year. And the median was 11.50% per year.
Back to Basics: PB Ratio
VitaNova Life Sciences (OTCPK:VNOV) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, VitaNova Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VitaNova Life Sciences PB Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, VitaNova Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where VitaNova Life Sciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
VitaNova Life Sciences (VNOV) has a PB Ratio of 6.22 as of Jul. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on VitaNova Life Sciences and its competitors. This is near median its historical median of 6.22. Over the past decade, VitaNova Life Sciences' PB Ratio has ranged from 1.90 to 21.76.
Is VitaNova Life Sciences' PB Ratio too high?
VitaNova Life Sciences' current PB Ratio of 6.22 is near median its 10-year median of 6.22. Over the past 10 years, this metric has ranged from a low of 1.90 to a high of 21.76. The Medical Distribution industry median PB Ratio is 0.99. VitaNova Life Sciences' value of 6.22 is 528.3% above this industry median. Overall, VitaNova Life Sciences has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does VitaNova Life Sciences' PB Ratio compare to HKPD and COSM?
VitaNova Life Sciences' PB Ratio of 6.22 can be compared against companies in the Medical Distribution industry. The industry median PB Ratio is 0.99. VitaNova Life Sciences' value of 6.22 is 528.3% above this benchmark. Historically, VitaNova Life Sciences' own PB Ratio has ranged from 1.90 to 21.76 over the past decade. While the company's 10-year median is 6.22 vs. the industry median of 0.99, VitaNova Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Distribution company?
The median PB Ratio among Medical Distribution companies is 0.99, based on 111 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VitaNova Life Sciences's current PB Ratio of 6.22 is 528.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on VitaNova Life Sciences and its competitors. For the Medical Distribution industry, the median PB Ratio is 0.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VitaNova Life Sciences's current PB Ratio is 6.22, which is near median its own 10-year median of 6.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VitaNova Life Sciences stock overvalued right now?
VitaNova Life Sciences (VNOV) has a current PB Ratio of 6.22. The stock's GF Value™ is $5.95, compared to a current price of $1.38 — trading 76.8% below its estimated fair value. The current PB Ratio is 6.22, which is near median its 10-year median of 6.22 and 528.3% above the Medical Distribution industry median of 0.99. VitaNova Life Sciences' overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For VitaNova Life Sciences (VNOV), the current PB Ratio is 6.22 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VitaNova Life Sciences (VNOV) Overvalued in 2026?
Based on GuruFocus' analysis, VitaNova Life Sciences stock appears to be undervalued.
The current stock price of $1.38 is trading 76.8% below its estimated GF Value™ of $5.95.
Key valuation signals for VNOV:
PB Ratio: 6.22 (near median its 10-year median of 6.22)
GF Value™: $5.95 vs. price of $1.38 (76.8% below fair value)
Industry Position: 528.3% above the Medical Distribution median
No single metric tells the full story. See the VNOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VitaNova Life Sciences Corp, formerly Yijia Group Corp provides business consulting services to domestic and international customers. The Company provides consulting services to its clients with regards to funding and other financial matters.The company's operating segments are The consulting services Segment mainly provides consulting advisory services in management, business, accounting and finance; and the Healthcare Segment mainly provides healthcare products and health consultation services to customers. The sale and distribution of healthcare products, such as Nicotinamide Riboside capsules, has only one performance obligation under the fixed-fee arrangements. and the majority of its revenue generates from Sales of healthcare products.
51GF Score
Get the complete analysis for VNOV
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VNOV has been successfully added to your 
